American International Group Inc. Raises Stock Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

American International Group Inc. lifted its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 1.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 116,671 shares of the medical equipment provider’s stock after buying an additional 1,488 shares during the period. American International Group Inc.’s holdings in Intuitive Surgical were worth $39,360,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Baystate Wealth Management LLC grew its position in Intuitive Surgical by 150.0% during the 4th quarter. Baystate Wealth Management LLC now owns 75 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 45 shares during the last quarter. MCF Advisors LLC boosted its holdings in shares of Intuitive Surgical by 108.1% in the 4th quarter. MCF Advisors LLC now owns 77 shares of the medical equipment provider’s stock valued at $26,000 after acquiring an additional 40 shares during the last quarter. Headinvest LLC purchased a new stake in shares of Intuitive Surgical in the 3rd quarter valued at $28,000. Able Wealth Management LLC purchased a new stake in shares of Intuitive Surgical in the 4th quarter valued at $28,000. Finally, Stone House Investment Management LLC boosted its holdings in shares of Intuitive Surgical by 100.0% in the 3rd quarter. Stone House Investment Management LLC now owns 100 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 50 shares during the last quarter. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently commented on ISRG. Stifel Nicolaus upped their price objective on shares of Intuitive Surgical from $420.00 to $430.00 and gave the company a “buy” rating in a report on Monday, April 8th. Piper Sandler upped their price objective on shares of Intuitive Surgical from $425.00 to $435.00 and gave the company an “overweight” rating in a report on Friday, April 19th. The Goldman Sachs Group started coverage on shares of Intuitive Surgical in a research note on Thursday, May 30th. They issued a “buy” rating and a $500.00 target price for the company. Robert W. Baird decreased their target price on shares of Intuitive Surgical from $440.00 to $436.00 and set an “outperform” rating for the company in a research note on Friday, April 19th. Finally, BTIG Research boosted their target price on shares of Intuitive Surgical from $412.00 to $421.00 and gave the company a “buy” rating in a research note on Friday, April 19th. Five investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $403.67.

Insider Activity at Intuitive Surgical

In other Intuitive Surgical news, SVP Mark Brosius sold 175 shares of the stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $389.16, for a total transaction of $68,103.00. Following the completion of the transaction, the senior vice president now owns 883 shares of the company’s stock, valued at $343,628.28. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other Intuitive Surgical news, EVP Robert Desantis sold 1,498 shares of the stock in a transaction dated Friday, April 26th. The shares were sold at an average price of $369.92, for a total transaction of $554,140.16. Following the completion of the transaction, the executive vice president now owns 5,507 shares of the company’s stock, valued at $2,037,149.44. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Mark Brosius sold 175 shares of the stock in a transaction dated Monday, May 13th. The stock was sold at an average price of $389.16, for a total transaction of $68,103.00. Following the transaction, the senior vice president now directly owns 883 shares of the company’s stock, valued at approximately $343,628.28. The disclosure for this sale can be found here. Over the last quarter, insiders sold 17,956 shares of company stock valued at $6,927,011. 0.90% of the stock is owned by company insiders.

Intuitive Surgical Price Performance

Shares of ISRG traded up $2.88 during mid-day trading on Friday, reaching $425.78. The stock had a trading volume of 940,996 shares, compared to its average volume of 1,163,301. Intuitive Surgical, Inc. has a 52-week low of $254.85 and a 52-week high of $428.86. The business’s fifty day moving average is $392.70 and its 200 day moving average is $374.43. The firm has a market cap of $151.02 billion, a price-to-earnings ratio of 76.86, a P/E/G ratio of 5.50 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings data on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.40 by $0.10. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The firm had revenue of $1.89 billion during the quarter, compared to analyst estimates of $1.87 billion. During the same quarter in the prior year, the firm posted $1.00 earnings per share. Intuitive Surgical’s quarterly revenue was up 11.5% on a year-over-year basis. As a group, sell-side analysts anticipate that Intuitive Surgical, Inc. will post 4.8 EPS for the current fiscal year.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.